NDA 209471 · Aft Pharms US
Combogesic
Acetaminophen, Ibuprofen · Oral · Nonsteroidal Anti-inflammatory Drug
Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Mar 1, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,695
325 Phase 3, 144 recruiting
FAERS reports
219
18 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY, CARDIOVASCULAR RISK, AND GASTROINTESTINAL RISK WARNING: HEPATOTOXICITY, CARDIOVASCULAR RISK AND GASTROINTESTINAL RISK See full prescribing information for complete boxed warning . COMBOGESIC contains acetaminophen, which has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with doses of acetaminophen that exceed 4,000 milligrams per day, and often involve more than one acetaminophen containing product ( 5.1 ). Nonsteroidal anti-inflammatory drugs (NSAIDS), like the ibuprofen in COMBOGESIC, cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use ( 5.2 ). COMBOGESIC tablets are contraindicated in the setting of...
What it is approved for
From the label in effect Nov 10, 2026.
COMBOGESIC is indicated in adults for the short-term management of mild to moderate acute pain. COMBOGESIC is a combination of acetaminophen and ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), and is indicated in adults for the short term management of mild to moderate acute pain ( 1 ).
Mechanism: Analgesia COMBOGESIC contains acetaminophen and ibuprofen. Acetaminophen is a non-opiate, non-salicylate analgesic. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to primarily involve central actions. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID). Its mechanism of action for analgesia, like that of other NSAIDs, is not completely understood, but involves inhibition of cyclooxygenase (COX-1 and COX-2). Ibuprofen is a potent inhibitor of prostaglandin synthesis in vitro. Prostaglandins sensitize afferent nerves and potentiate...
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- COMBOGESIC · ACETAMINOPHEN 325MG; IBUPROFEN 97.5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Acetaminophen" as an intervention, any sponsor and status, largest first.
OMNI Medical Services, LLCResearch network
NCT03944447 · 200,000 participants (planned) · Start Dec 1, 2018 · Primary completion Dec 31, 2025
Drug: Cannabis, Medical · For: Chronic Pain; Chronic Pain Syndrome; Chronic Pain Due to Injury and 30 more
Sites: Boca Raton, Florida; Bradenton, Florida; Fort Lauderdale, Florida · 17 sites in all
- A Study of a Candidate COVID-19 Vaccine (COV003)Pivotal-lookingStatus unknown
University of OxfordAcademic, hospital or other
NCT04536051 · 10,300 participants (planned) · Start Jun 2, 2020 · Primary completion Sep 2021
Drug: ChAdOx1 nCoV-19 single dose + paracetamol; MenACWY single dose + paracetamol and 2 more · For: Coronavirus
Sites: Salvador, Brazil; Natal, Brazil; Porto Alegre, Brazil · 6 sites in all
- Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTsPivotal-lookingCompleted
Mbarara University of Science and TechnologyAcademic, hospital or other
NCT00720811 · 6,456 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Artemether-lumefantrine combination; amoxycillin and 2 more · For: Malaria; Pneumonia
Sites: Saponé, Burkina Faso; Kassane, Ghana; Iganga, Uganda · 4 sites in all
- To Relieve Pain and Anxiety - an Intervention Study in Ambulance ServicesPivotal-lookingCompleted
Sahlgrenska University HospitalAcademic, hospital or other
NCT00792181 · 2,800 participants (planned) · Start Jun 2008 · Primary completion Nov 2008
Drug: Midazolam · For: Acute Myocardial Infarction; Pain
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis PainPivotal-lookingCompleted
Johns Hopkins UniversityAcademic, hospital or other
NCT04504812 · 1,937 participants · Start Feb 1, 2021 · Primary completion Apr 8, 2025
Drug: Duloxetine · For: Knee Osteoarthritis
Sites: Sacramento, California; San Diego, California; Aurora, Colorado · 24 sites in all
- Intravenous Acetaminophen for Postoperative Delirium in Older Patients Recovering From Major Noncardiac SurgeryPivotal-lookingNot yet recruiting
RenJi HospitalAcademic, hospital or other
NCT06653465 · 1,930 participants (planned) · Start Jun 2025 · Primary completion Jun 2027
Drug: Acetaminophen; Saline · For: Delirium in Old Age
- Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache PatientsPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02183688 · 1,889 participants · Start Sep 1998 · Primary completion Jan 2003
Drug: Low dose ASA; High dose ASA and 4 more · For: Migraine Disorders
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective47
- drug effective for unapproved indication30
- therapeutic product effect incomplete27
- drug effect less than expected15
- underdose13
- overdose10
- incorrect dose administered9
- drug ineffective for unapproved indication8
- hypersensitivity8
- off label use7
- inappropriate schedule of product administration6
- drug hypersensitivity5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2023 | 108 |
| 2024 | 55 |
| 2025 | 43 |
| 2026 | 12 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis.
Tan E, Braithwaite I, McKinlay CJD, et al. · JAMA Netw Open 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Tramadol (with or without acetaminophen) efficacy and harm: Systematic review and meta-analysis.
Otte JA, Chu G, Heran B, et al. · Can Fam Physician 2025 · Systematic Review, Meta-Analysis
- Acute Postoperative Pain Due to Dental Extraction in the Adult Population: A Systematic Review and Network Meta-analysis.
Miroshnychenko A, Ibrahim S, Azab M, et al. · J Dent Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
Cameron C, Kelly S, Hsieh SC, et al. · Headache 2015 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Bannuru RR, Schmid CH, Kent DM, et al. · Ann Intern Med 2015 · Research Support, N.I.H., Extramural, Systematic Review
- Short-term Dual Therapy or Mono Therapy With Acetaminophen and Ibuprofen for Fever: A Network Meta-Analysis.
De la Cruz-Mena JE, Veroniki AA, Acosta-Reyes J, et al. · Pediatrics 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Aft Pharms US
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.